Navigation Links
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
Date:6/8/2009

t-Batar, A., and Minnasch, P.

Method

Responder analysis of at least 1-point improvement from baseline to week 4 on the Disability Assessment Scale [DAS] for the primary therapeutic target after injection of a 20 U/mL dilution or 50 U/mL dilution was evaluated. After injection, observation over a 12-week period was followed by 8 weeks safety follow-up. Botulinum neurotoxin doses were derived from the recommendations from the organization WE MOVE. The individual injection pattern was adapted to patient's needs. A two-sided 95% Newcombe-Wilson confidence interval [CI] for the difference between groups was calculated.

Results

192 patients with upper limb spasticity caused by either stroke (88%), brain injury (5.7%), multiple sclerosis (0.5%) or cerebral palsy (1.6%) were randomized to the 50 U/mL dilution group (95 patients) or to the 20 U/mL dilution group (97 patients). Limb position (60.4%), Dressing (24.0%), Hygiene (9.4%) and Pain (6.3%) were chosen as primary therapeutic target on the DAS. The maximum injected total dose was 495 units NT 201. Four weeks after injection 57.1% of patients had an at least 1-point DAS reduction from the baseline score for their primary therapeutic target. No dilution group was inferior to each other regarding efficacy. 79.9% of patients and 89.0% of investigators reported an improvement in global assessment of efficacy at week 4. There were no relevant differences regarding safety between groups.

About Merz

Merz (KGAa) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in research and development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic dermatology, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fi
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
2. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
3. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
8. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
10. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
11. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today ... at 1802 South First St. in the Temple Medical and ... City of Temple to receive funding for ... Texas Veterans Health Care System, the new facility will enable ... biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 XRpro Sciences, Inc., ... discovery and development services which features high throughput ... industry, announced financial results for the year ended ...  Tyson, Chairman of XRpro Sciences commented, "We have ... from development stage to commercial stage in large ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... Life Sciences Holdings, Inc. (OTC Bulletin ... in the discovery, development and commercialization of novel drugs ... diseases, announced today that Dawson James Securities Inc., has ... report highlights Restanza™ (cethromycin) as a promising late-stage antibacterial ...
... 2010 HealthLeaders-InterStudy, a leading provider of managed ... a shift toward coordinated patient care in Portland, ... to the Portland, Maine Market Overview, ... coordinated care models such as patient-centered medical homes ...
Cached Medicine Technology:Dawson James Initiates Research Coverage of Advanced Life Sciences 2Dawson James Initiates Research Coverage of Advanced Life Sciences 3Consolidated Portland, Maine Healthcare Market Will Hamper Pharmaceutical Reps' Access to Physicians 2
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
(Date:3/28/2015)... Paso Robles, CA (PRWEB) March 28, 2015 ... damage restoration specialists , this week released a report ... worsen the symptoms of asthma sufferers, and according to ... healthy children. , According to the Environmental Protection ... can develop asthmatic reactions. Breathing in mold may trigger ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... from dating experts Samantha Sanderson and Jason Rogers has ... buzz of media attention. The commotion surrounding the course's ... prompting him to publish an in-depth review of the ... when the men in their lives suddenly start pulling ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
Breaking Medicine News(10 mins):Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
... of Matthew L. Myers, President, Campaign for ... following is a,statement of Matthew L. Myers, President, ... for Latin America and the world, both the,Mexico ... Tuesday,took significant action to reduce tobacco use and ...
... 2008) MIT graduate student and synthetic biologist ... pose threats to human health. His current mission: ... M.D. candidate and Ph.D. in the Harvard-MIT Division ... $30,000 Lemelson-MIT Student Prize for inventing processes that ...
... Bradley Kropp of Faculty of 1000 Medicine, researchers find ... of bowel function after gastrointestinal surgery a problem ... , Authors of the paper published in Urology evaluated ... them 5 pieces of chewing gum per day after ...
... TRAVERSE CITY, Mich., Feb. 27 Versus,Technology, Inc. ... its first fiscal quarter ended January 31, 2008, ... same quarter of the prior,year. Versus, quarterly revenues ... of major customer projects. Accordingly, the revenues,reported in ...
... by Swiss-Based In-House Counsel, To Proceed against Altria Group, Inc. and ... ... Inc., NEW YORK, Feb. 27 Broach & Stulberg, LLP announced,today ... for the Southern District of New York has denied motions to,dismiss age ...
... Feb. 27 To coincide with the annual,HIMSS ... announced a new release and new pricing of,its ... users,of EMR (Electronic Medical Records) software to scan ... package which is hosted on,Citrix(R) or Windows Terminal ...
Cached Medicine News:Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 2Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 2Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 4Health News:Versus Technology Announces First Quarter Results 2Health News:Versus Technology Announces First Quarter Results 3Health News:Versus Technology Announces First Quarter Results 4Health News:Versus Technology Announces First Quarter Results 5Health News:Versus Technology Announces First Quarter Results 6Health News:Court Denies Tobacco Giants' Motions to Dismiss Claims Alleging Explicit Age Discrimination and Retaliation 2Health News:Court Denies Tobacco Giants' Motions to Dismiss Claims Alleging Explicit Age Discrimination and Retaliation 3Health News:RemoteScan - Scanner Connectivity Software for EMR (Electronic Medical Record) Systems 2
... has created this extremely versatile and efficient ... liquid handling. With EDOS, high sample throughput ... with ease. ,The smallest volume that ... corresponding Combitip. The easy-to-follow user menus presented ...
... Dilutor-Dispenser is designed to transfer ... the clinical, biological, and chemical ... and performance as Gilsons other ... is ideal for routine laboratory ...
... synQUAD technology is a patented non-contact dispensing ... with a microsolenoid valve and stage stepper ... of liquid onto various slides, plates, or ... well, coefficient of variation (CVs) are less ...
16 channel Parallel dispenser using Positive Air Displacement Technology...
Medicine Products: